Intellectual Property Dispute Stalls WHO Decision On Global AMR Strategy
A dispute over intellectual property rights has stalled the World Health Organization’s (WHO) progress on a new global strategy to combat antimicrobial resistance (AMR). The delay occurred during a meeting of the WHO Executive Board on Wednesday, February 4, 2026, forcing further informal talks before a final decision can be reached.
A Pause in Global Strategy
The WHO Executive Board approved a compromise proposed by Nepal and Ethiopia to reopen negotiations specifically regarding “voluntary and mutually agreed technology transfers.” This procedural move prevented the adoption of the draft Global Action Plan on AMR, pushing a final consensus to a later date. The plan aims to preserve the efficacy of medicines by reducing bacterial AMR-associated human deaths by 10% by 2030 compared to the 2019 baseline.
What are Voluntary Technology Transfers?
Voluntary and mutually agreed technology transfers involve negotiated agreements where the owner of technology shares expertise, skills, or intellectual property with another party on agreed-upon terms. This differs from compulsory licensing, where governments can authorize manufacturing without the patent holder’s consent in certain emergency situations.
Points of Contention
Brazil initially challenged the draft plan, arguing that “voluntary” transfer rules could create dependency for developing nations. Delegates from Colombia and Indonesia expressed concerns that the plan might limit governments’ abilities to demand local manufacturing under international trade law. Switzerland countered that the text was largely technical and urged against reopening debate on an urgent global issue, a position Brazil refuted.
Ethiopia proposed limiting further consultations to the contested technology transfer language, a compromise that was adopted by the board. This ensures the broader technical work remains intact while allowing for continued political debate before the World Health Assembly in May.
The Importance of a “One Health” Approach
The draft plan emphasizes a “prevention-first” approach, focusing on infection control, vaccination and biosecurity across human, animal, and environmental sectors. It also highlights a “One Health” approach, integrating agricultural and environmental data to detect hotspots and prevent pollution.
A Divide Between Nations
High-income nations, including the United Kingdom and Japan, advocated for the plan’s swift adoption, citing prior consultations. Spain, representing the European Union, praised the plan’s “balanced approach” to public-private cooperation. Conversely, Indonesia and South Africa aligned with Brazil, asserting that current technology transfer specifications restrict the policy options available to developing nations.
The African Region, represented by Cameroon, emphasized the need for “stable and sustainable financing” to ensure national action plans can be implemented effectively. Non-state actor Médecins sans frontières (MSF) called for sustainable financing and a focus on identifying barriers to treatment access to ensure equity.
The Market Failure and Intellectual Property
The dispute stems from a unique market failure in the antibiotic sector. Regulations requiring careful antibiotic use limit sales and revenue, discouraging investment in new drug development. The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) stressed the importance of “effective R&D incentives.”
Frequently Asked Questions
What is antimicrobial resistance?
AMR occurs when pathogens evolve to withstand medicines, threatening to reverse decades of medical progress by rendering standard treatments ineffective.
What is the goal of the Global Action Plan on AMR?
The draft plan for 2026-2036 aims to preserve the efficacy of medicines by reducing bacterial AMR-associated human deaths by 10% by 2030 compared to the 2019 baseline.
What role did Nepal and Ethiopia play in the delay?
Nepal and Ethiopia proposed a compromise to reopen negotiations on intellectual property and technology transfer rights, which ultimately led to the delay in adopting the Global Action Plan on AMR.
As negotiations continue, will a consensus be reached that balances innovation with equitable access to essential medicines?